We ligated LLT1 on NK92 cells with CD161 on target cells and analysed IFN-γ production in the presence Histone Methyltransferase inhibitor of pharmacological inhibitors specific for various signalling mechanisms. These results indicate that LLT1 employs Src-PTK, p38 and ERK signalling pathways, but not PKC, PI3K or calcineurin. Phosphorylation studies of the signalling adaptor molecules confirmed that the ERK signalling pathway is associated with LLT1-mediated IFN-γ production. LLT1 ligation is not associated with any change in detectable IFN-γ mRNA levels suggesting that LLT1-stimulated IFN-γ production in NK cells may involve post-transcriptional or translational events. Natural

killer (NK) cells form the first line of defense against various tumours and a diverse range of pathogens. Unlike T-lymphocytes, NK cells do not recognize a specific antigen but rather detect changes in the expression of various surface molecules that may be indicative of infection or cancer. Alteration or downregulation of MHC class I receptors is recognized by NK cells and sufficient to stimulate killing of cells that otherwise would escape targeting by MHC class I dependent click here cytotoxic T-cells. The ability of tumour

cells to be killed by NK cells is inversely proportional to MHC class I receptor expression by the tumour cells and this has formed the basis for the “missing self hypothesis” describing the interactions between NK cells and their targets [1, 2]. NK surface receptors

are associated with a very diverse population of ligands in addition to the traditional MHC class I ligands [3, 4]. Multiple families of NK inhibitory Megestrol Acetate and activating receptors exist, and some receptors such as 2B4 (CD244) may function as an activating or inhibitory receptor under different conditions [5–7]. Activating receptors may regulate cytotoxicity, cytokine secretion or a combination of both [8, 9]. Lectin-like transcript 1 (LLT1) or CLEC2D or osteoclast inhibitory lectin (OCIL) is a human NK cell activating receptor [10, 11]. LLT1 is expressed on NK cells, T cells, monocytes/macrophages, and activated B cells and dendritic cells. Functional analysis indicates that LLT1 plays an activating role on NK cells by way of stimulating IFN-γ secretion [11]. LLT1 has also been shown to have a role on non-immune cells, inhibiting the formation and function of osteoclasts [12]. The natural ligand of LLT1 has been identified as CD161 (NKR-P1A), an NK cell inhibitory receptor known to play an important role in immune regulation [13, 14]. Expression of LLT1 on activated B cells and dendritic cells suggest that it might regulate cross-talk between NK cells and antigen presenting cells [15]. Human glioblastoma has been shown to increase LLT1 surface expression to facilitate escape from the immune system, presumably by inhibiting NK cell killing via ligation of the inhibitory CD161 receptor [16].